NEW YORK (Reuters Health) - J591, an anti-prostate specific membrane antigen monoclonal antibody, has shown promise in a phase I trial in patients with androgen specific prostate cancer, researchers report in the July 1st issue of the Journal of Clinical Oncology.
Senior investigator Dr. Neil H. Bander told Reuters Health that the agent “can target prostate cancer metastases wherever they are in the body.”
Accumulation of isotope-tagged antibody at tumor sites, he added, “led to the delivery of therapeutic radiation only to tumor sites but not to normal tissues. As a result, patients tolerated the treatment very well.”
In particular, Dr. Bander of Cornell University Medical Center and colleagues used escalating doses of yttrium-90-labeled J591 in 29 patients with androgen-independent prostate cancer.
No human antihuman antibody response was seen and nonhematologic toxicity was not dose-limiting.
One patient showed an 85% decline in prostate specific antigen (PSA) levels which lasted for 8 months. Another had a decline of 70% for 8.6 months. Moreover, an additional 6 patients experienced PSA stabilization.
Thus, Dr. Bander continued, “the potential benefit of this treatment approach was further supported by the finding of several significant anti-tumor responses.”
“A phase II trial is approved, " he concluded, “and expected to begin in the near future.”
Source: J Clin Oncol 2004;22:2522-2531. [ Google search on this article ]
MeSH Headings:Genital Neoplasms, Male: Neoplasms: Neoplasms by Site: Prostatic Neoplasms: Urogenital Neoplasms: DiseasesCopyright © 2002 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
